TCGA-33-4586-01A-01R-1443-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- MYC_TARGETS_V1+0.500
- G2M_CHECKPOINT+0.490
- UNFOLDED_PROTEIN_RESPONSE+0.470
- MTORC1_SIGNALING+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- MYC_TARGETS_V2+0.390
- DNA_REPAIR+0.380
- PROTEIN_SECRETION+0.380
- OXIDATIVE_PHOSPHORYLATION+0.290
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.490
- ALLOGRAFT_REJECTION-0.480
- IL6_JAK_STAT3_SIGNALING-0.280
- INFLAMMATORY_RESPONSE-0.280
- KRAS_SIGNALING_UP-0.260
- COMPLEMENT-0.210
- COAGULATION-0.160
- IL2_STAT5_SIGNALING-0.140
- ANGIOGENESIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-00081 | — | cohortSQ2 | 0.910 |
| 2 | TCGA-21-1072-01A-01R-0692-07 | — | cohortSQ2 | 0.909 |
| 3 | TCGA-22-5473-01A-01R-1635-07 | — | cohortSQ2 | 0.890 |
| 4 | TCGA-43-A474-01A-11R-A24H-07 | — | cohortSQ2 | 0.889 |
| 5 | TCGA-22-5482-01A-01R-1635-07 | — | cohortSQ2 | 0.889 |
| 6 | TCGA-GU-A42Q-01A-11R-A23W-07 | — | — | 0.889 |
| 7 | TCGA-68-7755-01A-11R-2125-07 | — | cohortSQ2 | 0.884 |
| 8 | TCGA-90-7769-01A-11R-2125-07 | — | cohortSQ2 | 0.882 |
| 9 | SRR12696752 | — | — | 0.882 |
| 10 | MDT-AP-0322 | Med | Medulloblastoma | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.470 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.290 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |